fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Kesimpta (ofatumumab) six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis – Novartis

Written by | 20 Apr 2024

Novartis announced new long-term data from the ALITHIOS open-label extension study showing that up to five years, patients treated earlier and continuously with Kesimpta (ofatumumab) had fewer disability… read more.

MHRA (UK) extends indication of Mavenclad (cladribine tablets) for relapsing forms of multiple sclerosis – Merck KGaA

Written by | 3 Apr 2024

Mavenclad (cladribine tablets) from Merck KGaA, is now indicated for the treatment of adult patients with relapsing forms of Multiple Sclerosis (MS) with active disease as defined by… read more.

Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko (natalizumab) in Germany

Written by | 5 Feb 2024

Sandoz announces the launch of Tyruko (natalizumab) in Germany from February Developed by Polpharma Biologics, Tyruko is the first and only biosimilar to treat RRMS.(r/r Multiple Sclerosis). Tyruko… read more.

Vanda Pharmaceuticals acquires U.S. and Canadian rights to Ponvory (ponesimod), a selective S1P1R modulator, approved for patients with relapsing multiple sclerosis

Written by | 15 Dec 2023

Vanda Pharmaceuticals Inc. announced that it has acquired U.S. and Canadian rights to Ponvory (ponesimod) from Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company. Ponvory is approved… read more.

European Commission approves Tyruko (natalizumab biosimilar), first and only biosimilar for multiple sclerosis in Europe – Sandoz

Written by | 2 Oct 2023

Sandoz, a global leader in generic and biosimilar medicines, announced that the European Commission (EC) granted marketing authorization for the first and only biosimilar Tyruko (natalizumab), developed by… read more.

FDA approves Tyruko, first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis – Sandoz

Written by | 6 Sep 2023

Sandoz, a global leader in generic and biosimilar medicines, announced that the FDA has approved its biosimilar Tyruko (natalizumab-sztn), developed by Polpharma Biologics. Tyruko is approved to treat… read more.

Examining when to get off meds for multiple sclerosis

Written by | 2 Aug 2023

Researchers at the Population Health Outcomes and Pharmacoepidemiology Education and Research Center (P-HOPER Center) at the University of Houston College of Pharmacy are examining when older patients with… read more.

Oral medication is the leading choice for multiple sclerosis treatment

Written by | 20 Jul 2023

The majority of individuals with multiple sclerosis (MS) treat the chronic and progressive neurological disorder with oral medications, likely because of many factors, including convenience, consumer advertising and… read more.

EU approves Briumvi in adults with relapsing multiple sclerosis – TG Therapeutics

Written by | 8 Jun 2023

TG Therapeutics announced that the European Commission (EC) has granted approval of Briumvi (ublituximab xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS)… read more.

Epstein-Barr virus may be leading cause of multiple sclerosis

Written by | 4 Feb 2022

Multiple sclerosis (MS), a progressive disease that affects 2.8 million people worldwide and for which there is no definitive cure, is likely caused by infection with the Epstein-Barr… read more.

European Commission approves Ponvory a once daily, oral therapy for the treatment of relapsing forms of multiple sclerosis – Janssen

Written by | 31 May 2021

Janssen, the Pharmaceutical Companies of Johnson & Johnson, announced that the European Commission (EC) has approved Ponvory (ponesimod) for the treatment of adult patients with relapsing multiple sclerosis… read more.

FDA issues complete response letter for Tysabri supplemental filing in SC form for multiple sclerosis – Biogen

Written by | 7 May 2021

Biogen Inc. announced that it has received a Complete Response Letter from the FDA for its supplemental Biologic License Application (sBLA) for a new subcutaneous route of administration… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.